ArisGlobal has created an Automation in Pharmacovigilance Knowledge Hub to help explain, in easily digestible terms, everything you need to know about automation in PV.

How far along are you in realizing benefits from automation? What is the biggest hindrance in adopting automation technologies? This two-part blog series analyzes polling responses from a recent DIA webinar and shares ArisGlobal’s thoughts on practical use cases for automation in pharmacovigilance and regulatory.

What is the greatest challenge across end-to-end pharma processes? How would you rate your automation capabilities? This two-part blog series analyzes attendee polling responses from a recent DIA webinar and shares ArisGlobal’s thinking about practical use cases for automation in pharmacovigilance and regulatory.

Recent advancements in technology are enabling automation to help address the growing PV challenges organizations face. Yet, when webinar attendees were asked “Does your company have a strategic plan for PV Automation?” responses were mixed.

This is the second in a three-part blog series on National Pharmacovigilance systems and the role of technology in bridging the gaps in pharmacovigilance of regulatory authorities around the world.

One of the key roles of pharmacovigilance departments is to understand the benefit-risk profile of a drug. But departments are often bogged down by manual tasks that can absorb time, which might be better spent on value-centric activities. Perhaps the most tedious pharmacovigilance activity is medical literature monitoring (MLM), and as we discussed in our last blog, manual, repetitive tasks are a primary cause of employee dissatisfaction.

On June 5th, 2019, ArisGlobal held a webinar focused on the “Key Use Cases of Automation in Pharmacovigilance.” During that event, 84% of attendees indicated a significant increase in their case volumes over the last five years. Only 15% considered their case volume increases to be ‘slight.’